with Joel de la Garza, Jonathan Lusthaus, and Hanne Tidnam (@omnivorousread)
The idea of the cybercriminal as lone wolf or hobby hacker is no longer much of a reality. Instead, the business of cybercrime looks a lot more just like that -- a large, global technology business, with many of the associated structures, challenges, and even casts of characters that legitimate businesses have.
In this conversation, a16z's Joel de la Garza, a16z operating partner for information security (formerly CSO of Box and head Citigroup's Cyber Intelligence Center), and Hanne Tidnam, discuss with Jonathan Lusthaus -- Director of the Human Cybercriminal Project at the University of Oxford -- the evolution of the industry of cybercrime from single perpetrator into a sprawling and sophisticated international industry as discussed in his new book, Industry of Anonymity: Inside the Business of Cybercrime.
A dive into the sociological, operational, and tactical realities of this murky underworld, Lusthaus and de la Garza discuss what the current industry has evolved into -- who the players are, what they are motivated by, and specialize in -- as well as how basic ideas like trust and anonymity function in a world where no one wants to get caught. How do criminal nicknames function as brand? Which countries tend to specialize in what kinds of crime, and why? And most of all, what changes when you begin to think of the business of cybercrime as an industry?
a16z Podcast: Pulse Check on Consumer Tech Trends 2019, CES and Beyond
with Benedict Evans (@benedictevans) and Steven Sinofsky (@stevesi)
Every year, the Consumer Electronics Show (CES) puts the latest and greatest developments in consumer technology on display in Vegas. But beyond the excitement and the hype, what's really here -- or not here -- to stay? Will televisions roll up into tiny boxes? Will Alexa find her way into electric carving knives? Which of these new gadgets will stand the test of time?
In this episode of the a16z podcast, Benedict Evans and Steven Sinofsky share their take not only on what this year’s show had to offer, but the broader trends at play. From the evolution of the smart home and voice interfaces to the cycle of bundling and unbundling and the future of TV and entertainment, the discussion is a pulse check on where we're at.
The content provided here is for informational purposes only, and does not constitute an offer or solicitation to purchase any investment solution or a recommendation to buy or sell a security; nor it is to be taken as legal, business, investment, or tax advice. In fact, none of the information in this or other content on a16z.com should be relied on in any manner as advice. Please see https://a16z.com/disclosures/ for further information.
This podcast may contain forward-looking statements relating to the objectives, opportunities, and the future performance of the U.S. market generally as well as specific publicly traded companies. Forward-looking statements may be identified by the use of such words as; “believe,” “expect,” “anticipate,” “should,” “planned,” “estimated,” “potential” and other similar terms. Examples of forward-looking statements include, but are not limited to, estimates with respect to financial condition, results of operations, and success or lack of success of any particular investment strategy. All are subject to various factors, including, but not limited to general and local economic conditions, changing levels of competition within certain industries and markets, changes in interest rates, changes in legislation or regulation, and other economic, competitive, governmental, regulatory and technological factors affecting a portfolio’s operations that could cause actual results to differ materially from projected results. Such statements are forward-looking in nature and involve a number of known and unknown risks, uncertainties and other factors, and accordingly, actual results may differ materially from those reflected or contemplated in such forward-looking statements. Prospective investors are cautioned not to place undue reliance on any forward-looking statements or examples. None of AH Capital Management, L.L.C. or any of its affiliates, principals, employees nor any other individual or entity assumes any obligation to update any forward-looking statements as a result of new information, subsequent events or any other circumstances. All statements made herein speak only as of the date that they were made.
a16z Podcast: Dark Data in Healthcare
with Susannah Fox (@susannahfox), Anil Sethi (@anilsethiusa / @ciitizencorp), Vijay Pande (@vijaypande), and Sonal Chokshi (@smc90)
The problem of "dark data" in healthcare isn't just a feel-good empowerment thing, but a structural issue that leads to miscommunication and extra friction, different players in the entire healthcare system not being able to collaborate with each other, and just major missed opportunities all round. And yes, it also leads to lack of empowerment for patients, not to mention doctors too (who often have less than 30 minutes on site to do their jobs).
But we already know all that. What's not clear is WHY and HOW is this the case, when the very point of HIPAA -- the Health Insurance Portability and Accountability Act (of 1996!) -- is to make data portable, not private. That is, IF patients know to ask for it... and can easily get it. So what if we could have a sort of permissioned "permissionless innovation" for healthcare data, not only bringing all that dark data to light, but more importantly -- borrowing from the history of internet innovation -- letting all sorts of expected and unexpected uses be built on top as a result? What happens when data and entities can talk to each other (à la APIs) through patients at the center of the circle of data?
From the Dr. Google problem (or opportunity!) to clinical trials and even the opioid crisis, we -- Susannah Fox (former CTO of the U.S. Department of Health and Human Services); Anil Sethi (CEO and founder of Ciitizen); and a16z bio general partner Vijay Pande; in conversation with Sonal Chokshi -- explore all this and more in this episode of the a16z Podcast. Let there be light!
a16z Podcast: The Science and Business of Innovative Medicines
with Vas Narasimhan (@vasnarasimhan), Jorge Conde (@jorgecondebio), Vijay Pande (@vijaypande), and Sonal Chokshi (@smc90)
On average, only 1 out of 20 medicines works when we actually bring them into the human body, and these rates of success haven't moved much in the pharma industry overall in the past 15 years, despite much scientific progress. Because if you really think about it, it's incredible that we find any human medicine that works at all, given that human beings are the product of billions of years of evolution, and represent an incredibly complex system we do not fully understand. Yet the business of the pharma industry -- and Novartis in particular, which covers everything from generics to innovative medicines -- is not that different from other large enterprises when it comes to managing R&D and pipelines of ideas, talent, and sales.
So in this conversation, a16z bio general partners Jorge Conde and Vijay Pande with Sonal Chokshi interview Vas Narasimhan, CEO of Novartis. How does the world's largest producer of medicines in terms of volume -- 70. billion. doses. a. year. -- balance the science and the business of innovation? How does an enterprise at such vast scale make decisions about what to build vs. buy, especially given the fast pace of science today? How does it balance attitudes between "not invented here" and "not invented yet"?
Narasimhan also takes us through the latest trends in therapeutics, such as cell and gene therapies (like CAR-T for cancer and more); RNA-based modalities; and others -- a sweeping tour from small molecules to large molecules to proteins and other modalities for making medicines. But where does tech come into all this, and where are we, really, on science becoming engineering? Why do both big companies and bio startups now need to get market value signals (not just approvals!) from payers earlier in the process of making therapeutics? And beyond all that, how could clinical trials be reinvented? Finally, what should all scientific (and all technical) leaders know when it comes to leadership? All this and more in this episode of the a16z Podcast, recorded recently on the road while at the J.P.M. health conference in San Francisco.
a16z Podcast: All About Synthetic Biology
with James J. Collins, Vijay Pande (@vijaypande), and Hanne Tidnam (@omnivorousread)
The idea of 'designing biology' -- once science fiction -- has over the last 20 years become just... science. In this episode, a16z bio general partner Vijay Pande with Hanne Tidnam talk all about the field of synthetic biology with James J. Collins, professor of bioengineering at MIT. Collins, whose work in synthetic biology and systems biology pioneered the field, has also launched a number of companies and received numerous awards and honors (including a MacArthur "Genius" Award, an NIH Director's Pioneer Award, and Sanofi-Institut Pasteur Award).
This wide-ranging conversation about the birth of synthetic biology covers everything from the founding story of the discipline to what "engineering and designing" biology really looks like in action -- when instead of engineering electrons, you are engineering toggle switches for genes -- to the disciplinary differences (and synergies) between how biologists and engineers see the world. What are the engineering and design principles, techniques, approaches that work best when applied to science? How does building a company in this new space look different, in terms of platforms and products? And how is this new field changing education in science, all the way down to kits that allow you to play with the machinery of a cell... at home... and even in middle school?